|
|
|
|
||
Re: Ability to ChargeAgree current available doses would be no charge. Stockpiling which is likely next step would probably be at cost plus an agreed markup based on the same terms as the DOD development contract. The Ebola drug is not going to carry the same margins as an HBV or cancer drug. It will have a major impact based on volume and its "proof of concept" impact on Tekmira's rnai delivery platform. |
return to message board, top of board |